A Study of Patients With HER2-Positive Metastatic Breast Cancer
NCT00105456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2010-05-06
Summary
This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.
Conditions
Sponsors & Collaborators
-
Genentech, Inc.
lead INDUSTRY
Principal Investigators
-
Isaiah Dimery, M.D. · Genentech, Inc.
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-03-31
- Completion
- 2009-05-31
More Related Trials
-
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
NCT01924351 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer
NCT00477139 ·Status: COMPLETED
-
Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
NCT05034393 ·Status: COMPLETED
-
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
NCT05893966 ·Status: RECRUITING
-
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116 ·Status: RECRUITING
-
Discordant HER2/Neu Status of Breast Cancer.
NCT01935739 ·Status: COMPLETED
-
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
NCT07217990 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT05736367 ·Status: RECRUITING ·Phase: NA
-
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
NCT05804578 ·Status: RECRUITING
-
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
NCT04247035 ·Status: UNKNOWN
-
TME Alteration in HER2 Positive Breast Cancer
NCT06533670 ·Status: ACTIVE_NOT_RECRUITING
-
The Treatment Situation of Chinese County Population With Breast Cancer
NCT05544123 ·Status: UNKNOWN
-
Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2
NCT00071383 ·Status: COMPLETED
-
Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype
NCT06813456 ·Status: RECRUITING
-
Tw HER2 Positive Breast Cancer Productivity & Utility Study
NCT04011085 ·Status: UNKNOWN
-
Study of Blood Samples in Patients With Breast Cancer
NCT00959556 ·Status: COMPLETED
-
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
NCT04368442 ·Status: UNKNOWN
-
Breast Cancer Molecular Analysis Protocol
NCT01855503 ·Status: COMPLETED
-
Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer
NCT04661982 ·Status: ACTIVE_NOT_RECRUITING
-
Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer
NCT05734950 ·Status: UNKNOWN
-
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
NCT07132502 ·Status: NOT_YET_RECRUITING
-
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy
NCT00530569 ·Status: UNKNOWN
-
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
NCT04925856 ·Status: RECRUITING ·Phase: NA
-
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
NCT05510037 ·Status: COMPLETED
-
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT04273555 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2